key: cord-0771488-rpd6juqx
authors: Kon, Edo; Hazan-Halevy, Inbal; Rosenblum, Daniel; Cohen, Niv; Chatterjee, Sushmita; Veiga, Nuphar; Raanani, Pia; Bairey, Osnat; Benjamini, Ohad; Nagler, Arnon; Peer, Dan
title: Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection
date: 2020-06-07
journal: Pharmaceutics
DOI: 10.3390/pharmaceutics12060520
sha: cea2fbed0a49a9fd56371f1f35ddb35b569303aa
doc_id: 771488
cord_uid: rpd6juqx

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western populations. Therapies such as mRNA and siRNA encapsulated in lipid nanoparticles (LNPs) represent a clinically advanced platform and are utilized for a wide variety of applications. Unfortunately, transfection of RNA into CLL cells remains a formidable challenge and a bottleneck for developing targeted therapies for this disease. Therefore, we aimed to elucidate the barriers to efficient transfection of RNA-encapsulated LNPs into primary CLL cells to advance therapies in the future. To this end, we transfected primary CLL patient samples with mRNA and siRNA payloads encapsulated in an FDA-approved LNP formulation and characterized the transfection. Additionally, we tested the potential of repurposing caffeic acid, curcumin and resveratrol to enhance the transfection of nucleic acids into CLL cells. The results demonstrate that the rapid uptake of LNPs is required for successful transfection. Furthermore, we demonstrate that resveratrol enhances the delivery of both mRNA and siRNA encapsulated in LNPs into primary CLL patient samples, overcoming inter-patient heterogeneity. This study points out the important challenges to consider for efficient RNA therapeutics for CLL patients and advocates the use of resveratrol in combination with RNA lipid nanoparticles to enhance delivery into CLL cells.

Chronic lymphocytic leukemia (CLL) is the most common leukemia, with 15,000 new diagnoses and claiming 5000 lives per year in the United States alone [1] [2] [3] [4] . The median age of CLL patients at diagnosis is above 70 years [1, 3] . The disease is characterized by the progressive aggregation of phenotypically mature non-functioning, non-proliferating malignant B lymphocytes arrested in the

Cells were plated at a density of 4 × 10 6 cells/well in 12-well plates covered with coverslips. Cells were transfected with 4 µg/mL of NC-Cy5-LNPs, and the transfection method was carried out as described. For Hoechst staining, plates were centrifuged and wells were washed with PBS and stained with 2.5 µg/mL Hoechst live staining for 30 min at 37 • C and 5% CO 2 . Next, plates were centrifuged again, washed with PBS, and fixated with 4% paraformaldehyde for 30 min at room temperature. After 30 min, the paraformaldehyde was aspirated and wells were blocked with 3% BSA for 1 h at room temperature. Cell membranes were stained with APC-αhuman CD44 (diluted 1:100 in 3% BSA) for 30 min at 4 • C in dark. Wells were washed twice with PBS and coverslips were mounted on slides and imaged by confocal microscopy.

Cells were plated at a density of 10 6 cells/well in 48-well plates, transfected with 2.5 µg/mL of luciferase mRNA encapsulated in LNPs. Expression was determined 24 h post-transfection according to the Promega kit protocol, relative luminescence units were determined by a Veritas™ microplate luminometer. Toxicity was determined 48h post transfection by PI ANNEXIN-V, as described previously.

Cells were plated at a density of 4 × 10 6 cells/well in 12-well plates, transfected with 4 µg/mL of siRNA targeted against Mcl-1, CD44, or STAT3 encapsulated in LNPs by directly adding LNPs to the media. Viability was assessed 48 h post transfection by PI ANNEXIN-V staining. Briefly, cells were collected, washed twice with PBS, and followed by a 15-min incubation at room temperature with 100µl of annexin binding buffer containing propidium iodide (1:40) and Annexin-APC (1:20) . Cell death percentage was determined by flow cytometry. The siRNA sequences employed in study: siMcl-1 sense: CCCGCCGAAUUCAUUAAUUUACUGT, anti-sense: ACAGUAAAUUAAUGAAUUCGGCGGGUA; siCD44 sense: GGCGCAGAUCGAUUUGAAUAUAACC, anti-sense: GGUUAUAUUCAAAUCGAUCUGCGCCCAG; siSTAT3 sense: CAGCAACACUCUUCAGUACAUAAUA, anti-sense: UAUUAUGUACUGAAGAGUGUUGCUGGA; siNC5 sense: CAUAUUGCGCGUAUAGUCGCGUUAG, anti-sense: UGGUAUAACGCGCAUAUCAGCGAAUC.

Total RNA was extracted from CLL cells with the Thermo Scientific GeneJET RNA Purification Kit, according to the manufacturer's protocol. The cDNA was synthesized from an initial amount of 500 ng of total RNA extracted with a qScript cDNA Synthesis Kit, according to the manufacturer's protocol. The cDNA was diluted 1:3 in nuclease-free water and RT-PCR was carried out. In all experiments, expression was normalized to subunit A of eukaryotic initiation factor 3 (eIF3A). Primer sequences employed in the study can be found in supplementary section (Table S2 ).

To transfect CLL cells with both siRNA and mRNA, we employed an FDA-approved lipid formulation of Dlin-MC3-DMA (MC3), cholesterol, DSPC, and PEG-DMG; mixed at a molar ratio of 50:38:10.5:1.5, respectively. This formulation is considered the current gold standard formulation for RNA-LNP therapy. It is approved as the siRNA LNP treatment ONPATTRO ® (patisiran), an RNAi Pharmaceutics 2020, 12, 520 5 of 13 therapeutic for hereditary transthyretin amyloidosis (hATTR [11, [26] [27] [28] . The LNPs were prepared by microfluidic mixing with the NanoAssemblerTM micromixer. This enables both high inter-batch reproducibility, as well as the intra-batch uniformity of LNPs. The hydrodynamic diameter of these LNPs was measured to be 73 ± 6.04 nm and 66 ± 3.94 nm for siRNA-and mRNA-encapsulating LNPs, respectively, with close to 100% encapsulation efficiency. Consistently uniform LNPs were formed with a polydispersity index (PDI) of <0.2, with a close to neutral zeta potential ( Figure 1B ). [11, [26] [27] [28] . The LNPs were prepared by microfluidic mixing with the NanoAssemblerTM micromixer. This enables both high inter-batch reproducibility, as well as the intra-batch uniformity of LNPs. The hydrodynamic diameter of these LNPs was measured to be 73 ± 6.04 nm and 66 ± 3.94 nm for siRNA-and mRNA-encapsulating LNPs, respectively, with close to 100% encapsulation efficiency. Consistently uniform LNPs were formed with a polydispersity index (PDI) of <0.2, with a close to neutral zeta potential ( Figure 1B ). 

First, we aimed to gain insight into the process of CLL cell transfection by RNA-LNPs. The efficient transfection of primary CLL cells with the FDA-approved LNP formulation remains a formidable challenge. Therefore, we aimed to understand the factors that impede this process. First, we characterized LNP uptake into CLL cells and interrogated how serum proteins affect LNP uptake into these cells. To test this, we co-incubated primary CLL cells with LNPs encapsulating a Cy5labeled negative control (NC) siRNA (NC-Cy5-LNPs) and measured the fluorescence of the CLL cells by flow cytometry at sequential time points. The incubation of NC-Cy5-LNPs with cells in serumfree media resulted in a rapid increase in LNP uptake compared to full media conditions (Figure 2A and 2B). The difference in uptake was most significant at the 25 min timepoint and gradually evened out ( Figure 2C ). The rapid uptake of NC-Cy5-LNPs in serum-free conditions was corroborated by confocal microscopy imaging ( Figure 2E ). Next, we aimed to understand how this rapid uptake affects LNP transfection. We incubated primary CLL patient samples with mRNA luciferaseencapsulating LNPs (mRNA-Luc) and measured luminescence 24 h post transfection. Interestingly, while the eventual uptake was nonsignificant, the rapid uptake did result in a significant increase in mRNA-Luc transfection. This was witnessed in all samples tested, overcoming interpatient heterogeneity associated with studies executed with primary cells ( Figure 2D ). From this, we conclude that the rate of LNP uptake is crucial for successful transfection in primary CLL cells. 

First, we aimed to gain insight into the process of CLL cell transfection by RNA-LNPs. The efficient transfection of primary CLL cells with the FDA-approved LNP formulation remains a formidable challenge. Therefore, we aimed to understand the factors that impede this process. First, we characterized LNP uptake into CLL cells and interrogated how serum proteins affect LNP uptake into these cells. To test this, we co-incubated primary CLL cells with LNPs encapsulating a Cy5-labeled negative control (NC) siRNA (NC-Cy5-LNPs) and measured the fluorescence of the CLL cells by flow cytometry at sequential time points. The incubation of NC-Cy5-LNPs with cells in serum-free media resulted in a rapid increase in LNP uptake compared to full media conditions (Figure 2A ,B). The difference in uptake was most significant at the 25 min timepoint and gradually evened out ( Figure 2C ). The rapid uptake of NC-Cy5-LNPs in serum-free conditions was corroborated by confocal microscopy imaging ( Figure 2E ). Next, we aimed to understand how this rapid uptake affects LNP transfection. We incubated primary CLL patient samples with mRNA luciferase-encapsulating LNPs (mRNA-Luc) and measured luminescence 24 h post transfection. Interestingly, while the eventual uptake was nonsignificant, the rapid uptake did result in a significant increase in mRNA-Luc transfection. This was witnessed in all samples tested, overcoming interpatient heterogeneity associated with studies executed with primary cells ( Figure 2D ). From this, we conclude that the rate of LNP uptake is crucial for successful transfection in primary CLL cells. 

Next, we screened three different plant-based polyphenols for the ability to enhance mRNA-Luc-LNP transfection. Plant-based polyphenols are reported to have innate anti-cancer properties and are suggested for the supplementation of cancer therapies. Therefore, we aimed to determine the ability to harness three safe and well-known polyphenols with RNA-LNP transfection. We chose to compare resveratrol, caffeic acid, and curcumin ( Figure 3A ). All of these plant-based polyphenols were reported to have anti-cancer properties [19] [20] [21] [22] . To evaluate the polyphenols' capabilities, we co-incubated mRNA-Luc-LNPs with primary CLL patient samples in serum-free media conditions for 1 h. After 1 h, 5-40 µM of resveratrol, caffeic acid, curcumin, and chloroquine were added to the wells. Chloroquine, an antimalarial that is known to affect the endolysosomal system, serves as a positive endosomal escape control in many studies due to increasing endosomal escape, was utilized as a positive control for our screen [29] [30] [31] . The optimal concentration of each agent was determined by the maximum enhancement of mRNA-Luc transfection measured after 24 h and minimal toxicity measured after 48 h ( Figure S2 ). The screen, performed on different patient samples, demonstrates that, of the polyphenols tested, both curcumin and resveratrol enhance transfection at low micro-molar concentrations ( Figure 3B ). Of these, resveratrol at 10 µM demonstrated the best potential for augmenting mRNA-Luc transfection into CLL cells with no toxicity ( Figure 3C) . Surprisingly, chloroquine treatment did not augment mRNA-Luc transfection ( Figure 3B ). Since we added resveratrol into our transfection protocol 1 h post transfection, after the LNP saturation of cells in serum-free conditions, we did not expect resveratrol to cause increased LNP uptake. To validate this, we co-incubated NC-Cy5-LNPs in serum-free media, added resveratrol, and determined whether uptake was enhanced. As expected, the addition of resveratrol did not affect LNP uptake ( Figure 3D,E) . This suggests that the resveratrol enhancement of transfection is not due to increased LNP uptake.

Next, we aimed to test if resveratrol augments siRNA-mediated gene silencing. First, we co-incubated primary CLL patient cells with Mcl-1-targeting siRNA encapsulated in LNPs (Mcl-1-siRNA). Mcl-1, a member of the Bcl-2 family, is over-expressed in CLL, as well as in other leukemias. Mcl-1 enhances CLL cell survival by inhibiting apoptosis and is associated with drug resistance [32] [33] [34] . Therefore, to evaluate siRNA transfection, we executed a phenotypic screen and determined cell viability 48 h post transfection ( Figure 4A ). To confirm that this phenotype is a result of Mcl-1 gene knockdown, we also measured gene expression ( Figure 4B ). The results demonstrate that the transfection enhancement by adding resveratrol with minimal to no toxicity was brought on by the process itself ( Figure 4A ,B). We could notice Mcl-1 gene silencing as early as 24 h post transfection and determined that, while there is an added benefit to transfection in serum-free media, administering resveratrol significantly enhances the transfection efficiency ( Figure 4B) .

Next, to demonstrate that this method can be applied to several genes, we chose to transfect primary CLL cells with LNPs encapsulating siRNA targeting CD44 and signal transducer and activator of transcription 3 (STAT3). STAT3 is important for CLL cellular growth, survival, and has a role in CLL immunosuppression and drug resistance [35] [36] [37] . CD44 is a well-known cancer stem cell-associated marker which has also been reported to participate in CLL cell survival [38, 39] . To this end, we transfected primary CLL cells with si-CD44 and si-STAT3 and determined CD44 and STAT3 gene expression levels ( Figure 4C,D) . These results demonstrate that resveratrol enhances not only mRNA, but also siRNA-LNP transfection. Pharmaceutics 2020, 12, 520 9 of 13 activator of transcription 3 (STAT3). STAT3 is important for CLL cellular growth, survival, and has a role in CLL immunosuppression and drug resistance [35] [36] [37] . CD44 is a well-known cancer stem cellassociated marker which has also been reported to participate in CLL cell survival [38, 39] . To this end, we transfected primary CLL cells with si-CD44 and si-STAT3 and determined CD44 and STAT3 gene expression levels ( Figures 4C,D) . These results demonstrate that resveratrol enhances not only mRNA, but also siRNA-LNP transfection. 

Herein, we interrogated the process of LNP uptake into primary CLL patient cells. We demonstrate how rapid the uptake of RNA-LNPs can lead to the efficient transfection of these cells. CLL cells, similar to most leukocytes, are notoriously hard to transfect with any tool in a non-toxic fashion. Additionally, while primary CLL cells survive for long periods in vivo, they undergo rapid apoptosis ex vivo, which complicates the ability to study primary patient samples [5, 40] . Furthermore, we demonstrate the capability of repurposing resveratrol as an RNA-LNP transfection enhancer for both mRNA and siRNA payloads, hinting at a possible shared mechanism. In our study, we employed an FDA-approved LNP formulation, which is considered the current gold standard formulation for RNA-LNP therapy. It is approved as an siRNA-LNP therapeutic for hereditary transthyretin amyloidosis (hATTR); ONPATTRO ® (patisiran), approved in 2018 [11, [26] [27] [28] . Furthermore, LNPs demonstrate acceptable toxicities and are currently assessed in clinical trials in the oncology field, as well as for prophylactic viral vaccines for many infections, including Zika (NCT04064905) and the novel SARS-CoV-2 (NCT04283461) [9, 41] .

Several interesting points remain to be elucidated following this study. First, the relationship between the short serum depletion and the dramatic increase in LNP uptake, which can be a result of either cellular changes or alterations in the LNP properties. Serum depletion can be related to metabolic stress and has been reported to induce G1/G0 cell cycle arrest [42, 43] . G1/G0 cell cycle arrest leads to increased endocytosis, the main pathway of LNP uptake into cells. Yet, CLL cells are already permanently arrested in the G1/G0 stage [5] . Further complicating the matter, several previous reports demonstrate that the absence of serum from media inhibits efficient transfection with LNPs. The relationship between serum presence and transfection efficacy is tricky to predict and is proposed to be related to the LNP formulation and cells targeted [44, 45] . Regarding LNPs' involvement, serum proteins can coat LNPs and alter their physical properties; this phenomenon is known as a "protein corona" [17] . While it is known, it is very hard to predict which protein corona enrichment pattern will emerge, since it depends on many factors, such as the formulation and type of PEG-lipids used [44] . In our study, we demonstrate that an important factor is the speed with which the primary cells are loaded with LNPs. It would be interesting to further interrogate and suggest a mechanism for this phenomenon. Furthermore, in future studies, we will attempt to address what is driving this rapid uptake to try to enhance this process to develop future targeted RNA-LNP-based therapeutics for CLL patients. In the study, we point out the importance of the kinetics of the uptake and demonstrate that the rapid uptake of LNPs is key to efficient transfection.

In our study, we have screened three plant-based polyphenols' ability to enhance RNA-LNP transfections. Resveratrol, caffeic acid, and curcumin have all been reported to have a myriad of therapeutic properties and are suggested to be quite safe for repurposing [19] [20] [21] [22] . In our screen, we have determined that resveratrol enhances both mRNA-and siRNA-LNP transfections. Since it assists both processes, we suspect that it enhances one of the stages shared by both mRNA and siRNA delivery, such as endosomal escape. Unfortunately, endosomal escape is extremely difficult to quantify in any cell, let alone primary leukocytes, which are small and have a minimal cytoplasmic volume. Furthermore, the process of the endosomal escape of RNA-LNPs is complex and is still being elucidated. Factors such as the molar ratios of ionizable lipids to mRNA nucleotides can modulate the efficiency of RNA-LNPs' endosomal escape efficiency, intracellular fate, and packaging into extracellular vesicles (EVs). Recently, it was reported that after transfection, LNP components (mRNA and ionizable lipids) are partly incoroporated into exocytosed EVs comprising the encapsulated mRNA and ionizable lipids that can be re-used to efficiently deliver nucleic acids into cells [46] .

Regarding resveratrol, several studies have accredited the molecule with cytotoxic and anti-leukemic properties, as well as a role in enhancing the current activity of chemotherapies [47] [48] [49] [50] . In CLL, this was attributed to a tumor-specific increase in apoptosis, associated with a decreased BCL2/BAX ratio [48] . In this study, we have optimized the concentration of resveratrol to be repurposed as a non-toxic transfection enhancer. In the future, it will be very interesting to assess and devise a strategy to combine RNA-LNP therapies with resveratrol supplementation, which can be harnessed for both ex vivo, as well as in vivo, targeted delivery schemes. This will include a therapy scheme involving the co-administration of resveratrol at optimal concentrations, together with RNA-LNPs. Interestingly, it has been suggested that resveratrol could be utilized as an ex vivo therapy to eliminate malignant cells (leukemia purging) during the process of autologous hematopoietic stem-cell transplantation (auto-HSCT) in leukemia patients, due to its proposed innate ability to kill cancer cells specifically [51, 52] . Eventually, the optimal in vivo therapy scheme we envision will involve resveratrol, administered together with RNA-LNPs, targeted against CLL cells. We have previously demonstrated a proof of concept of targeted RNA-LNPs for cancer therapeutics, including B cell malignancies [53, 54] .

In this study, we report that the rapid uptake of LNPs is key to the successful RNA-LNP manipulation of CLL cells and that the presence of serum slows down this effect. Importantly, we report the potential to harness resveratrol to enhance both mRNA-and siRNA-LNP-based manipulation of primary CLL patient cells.

Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/6/520/s1. Table S1: Table with patient characteristics. Table S2 : Primers employed in study for RT-PCR reactions. Figure S1 : Representative graph of CD5 + /CD19 + patient sample staining. Determined by flow cytometry. Figure Funding: This work was supported in part by the Dotan Hematology Center at Tel Aviv University and by the Lewis Trust for Blood Cancer Research, awarded to D.P.

Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century

Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI

Chronic Lymphocytic Leukemia: A Clinical Review

Evolution of CLL treatment-From chemoimmunotherapy to targeted and individualized therapy

Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids

The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL

Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia

An RNA toolbox for cancer immunotherapy

Therapeutic mRNA delivery to leukocytes

FDA new drug approvals in Q3 2018

Lipid nanoparticles for short Interfering RNA delivery

Non-viral Delivery of Nucleic Acids: Insight Into Mechanisms of Overcoming Intracellular Barriers

Efficient Non-Viral Transfection of CLL-B Cells with Human CD40 Ligand

Advances in lipid nanoparticles for siRNA delivery

On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA

Dan Peer Progress and challenges towards targeted delivery of cancer therapeutics

Endosomal Size and Membrane Leakiness Influence Proton Sponge-Based Rupture of Endosomal Vesicles

Natural polyphenols: An overview

The role of resveratrol in cancer therapy

Antiproliferative and apoptotic effects of caffeic acid on SK-Mel-28 human melanoma cancer cells

Curcumin inhibits cancer progression through regulating expression of microRNAs

Therapeutic potential of resveratrol: The in vivo evidence

Resveratrol as an anti-cancer agent: A review

Alnylam launches era of RNAi drugs

Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery

Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics

Imaging small molecule-induced endosomal escape of siRNA

Enhancing Endosomal Escape for Intracellular Delivery of

Toxicity of cationic lipids and cationic polymers in gene delivery

Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia

Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway

STAT3-induced SMYD3 transcription enhances chronic lymphocytic leukemia cell growth in vitro and in vivo

STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells

The role of CD44 in the pathophysiology of chronic lymphocytic leukemia

More than a mere stem cell marker

Establishment of cell lines derived from chronic lymphocytic leukaemic cells by transfection with myc and ras

Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility

Heat shock protein 27 promotes cell cycle progression by down-regulating E2F transcription factor 4 and retinoblastoma family protein p130

Regulation of the cell cycle via mitochondrial gene expression and energy metabolism in HeLa cells

The role of surface chemistry in serum protein corona-mediated cellular delivery and gene silencing with lipid nanoparticles

Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms

Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells

Resveratrol has anti-leukemic activity associated with decreased O-GlcNAcylated proteins

Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia

Resveratrol and quercetin-induced apoptosis of human 232B4 chronic lymphocytic leukemia cells by activation of caspase-3 and cell cycle arrest

Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma

Rationale for assessing the therapeutic potential of resveratrol in hematological malignancies

Resveratrol selectively inhibits leukemia cells: A prospective agent for ex vivo bone marrow purging

A modular platform for targeted RNAi therapeutics

Hazan-halevy, I. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.